Valuation: Karyopharm Therapeutics Inc.

Market Cap 213M 186M 172M 158M 298M 20.48B 304M 2.05B 805M 10B 798M 781M 34.53B P/E 2026 *
-2.25x
P/E 2027 * -3.02x
Enterprise Value 466M 407M 376M 345M 654M 44.86B 665M 4.49B 1.76B 21.91B 1.75B 1.71B 75.64B EV / Sales 2026 *
3.39x
EV / Sales 2027 * 1.37x
Free-Float
95.32%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Karyopharm Therapeutics Inc.

1 day-1.57%
1 week-8.04%
Current month-3.99%
1 month+3.08%
3 months+8.31%
6 months+48.65%
Current year+27.45%
1 week 9.36
Extreme 9.36
10.3
1 month 8.78
Extreme 8.78
10.86
Current year 5
Extreme 5
10.99
1 year 3.65
Extreme 3.6503
10.99
3 years 3.51
Extreme 3.51
29.25
5 years 3.51
Extreme 3.51
220.95
10 years 3.51
Extreme 3.51
444.15
Manager TitleAgeSince
Chief Executive Officer 58 03/05/2021
Director of Finance/CFO 55 03/01/2025
Chief Tech/Sci/R&D Officer - 01/04/2023
Director TitleAgeSince
Director/Board Member 62 01/01/2013
Director/Board Member 61 01/04/2013
Director/Board Member 78 03/10/2013
Date Insider Type Main position Quantity % Market Cap.
5/21/26 A Free

Director

15,508 0.0688%
5/21/26 A Free

Director

15,508 0.0688%
5/21/26 A Free

Director

15,508 0.0688%
Change 5-day change 1-year change 3-year change Capi.($)
-1.57%-8.04%+124.40%-59.91% 213M
+2.18%+1.65%+23.91%-5.51% 69.07B
-0.72%-0.59%+35.46%+194.04% 51.77B
+0.94%+39.60%+39.60%+39.60% 43.63B
+1.12%+0.35%-50.35%-52.35% 40.89B
+5.92%+5.03%+62.63%-25.10% 30.84B
-7.51%-17.52%+96.97%-47.96% 25.06B
+1.36%-1.58%+68.50%+88.88% 23.3B
-5.57%-0.84%-0.17%+182.38% 20.92B
-1.70%-2.84%+66.96%+122.45% 16.71B
Average -0.57%-2.21%+46.79%+43.65% 32.24B
Weighted average by Cap. +0.23%-1.36%+31.81%+47.13%

Financials

2026 *2027 *
Net sales 137M 120M 111M 102M 193M 13.22B 196M 1.32B 520M 6.46B 515M 504M 22.29B 155M 136M 126M 115M 218M 14.96B 222M 1.5B 588M 7.31B 583M 570M 25.23B
Net income -121M -106M -97.83M -89.77M -170M -11.66B -173M -1.17B -458M -5.69B -454M -445M -19.66B -135M -118M -109M -99.79M -189M -12.96B -192M -1.3B -509M -6.33B -505M -494M -21.85B
Net Debt 253M 221M 205M 188M 355M 24.38B 361M 2.44B 958M 11.9B 950M 929M 41.1B -
Logo Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Employees
228
Date Price Change Volume
16/07/26 $9.380 -1.57% 236,381
15/07/26 $9.530 -4.80% 316,488
14/07/26 $10.01 -0.40% 481,544
13/07/26 $10.05 -2.80% 431,397
10/07/26 $10.34 +1.37% 320,246
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.380USD
Average target price
13.50USD
Spread / Average Target
+43.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KPTI Stock